Inventor · disambiguated record
Yalda Bravo
Also filed as: BRAVO YALDA · BRAVO YALDA MOSTOFI
19 granted patents·8 pending applications·26 citations·filing 2011–2025
91Inventor score
Files withTEMPEST THERAPEUTICS INC13INCEPTION 2 INC3NOVIRA THERAPEUTICS INC3PIPELINE THERAPEUTICS INC3CONTINEUM THERAPEUTICS INC2
Top patents by PatentIndex Score
27 records- 0192US11752149B2Muscarinic acetylcholine M1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·3 cites·2 claims
- 0291US11795156B2Bicyclic carboxamides and methods of use thereofTEMPEST THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·26 claims
- 0391US11066405B2Bicyclic compounds and their use in the treatment of cancerTEMPEST THERAPEUTICS INC·Filed 2020·Granted Jul 20, 2021·3 cites·16 claims
- 0488US10968201B2Bicyclic carboxamides and methods of use thereofTEMPEST THERAPEUTICS INC·Filed 2019·Granted Apr 6, 2021·3 cites·17 claims
- 0586US11638704B2Bicyclic compounds and their use in the treatment of cancerTEMPEST THERAPEUTICS INC·Filed 2021·Granted May 2, 2023·1 cites·18 claims
- 0685US11512090B2Muscarinic acetylcholine M1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2019·Granted Nov 29, 2022·4 cites·19 claims
- 0785US2025353829A1Bicyclic carboxamides and methods of use thereofTEMPEST THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0884US12215093B2Bicyclic carboxamides and methods of use thereofTEMPEST THERAPEUTICS INC·Filed 2023·Granted Feb 4, 2025·0 cites·18 claims
- 0984US11472789B2Bicyclic carboxamides and methods of use thereofTEMPEST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·1 cites·18 claims
- 1080US11738009B2Bicyclic compounds and their use in the treatment of cancerTEMPEST THERAPEUTICS INC·Filed 2018·Granted Aug 29, 2023·1 cites·11 claims
- 1179US2024041837A1Triazolone compounds and uses thereofTEMPEST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1277US9597332B2Sulfide alkyl compounds for HBV treatmentNOVIRA THERAPEUTICS INC·Filed 2015·Granted Mar 21, 2017·1 cites·9 claims
- 1376US10196351B2Sulfide alkyl compounds for HBV treatmentNOVIRA THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·1 cites·19 claims
- 1474US12390462B2Muscarinic acetylcholine M1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·6 claims
- 1574US10568871B2Triazolone compounds and uses thereofTEMPEST THERAPEUTICS INC·Filed 2017·Granted Feb 25, 2020·1 cites·20 claims
- 1674US9676754B2Triazolone compounds and uses thereofINCEPTION 2 INC·Filed 2013·Granted Jun 13, 2017·2 cites·18 claims
- 1771US9776976B2Triazolone compounds and uses thereofINCEPTION 2 INC·Filed 2014·Granted Oct 3, 2017·2 cites·23 claims
- 1870US10710959B2Sulfide alkyl compounds for HBV treatmentNOVIRA THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·0 cites·8 claims
- 1969US11666557B2Triazolone compounds and uses thereofTEMPEST THERAPEUTICS INC·Filed 2019·Granted Jun 6, 2023·0 cites·19 claims
- 2069US9505728B2Triazolone compounds and uses thereofINCEPTION 2 INC·Filed 2013·Granted Nov 29, 2016·2 cites·25 claims
- 2165US2025222146A1Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses ThereofRAYZEBIO INC·Filed 2024·Application pending·0 cites
- 2257US2024217981A1Crystalline compound of muscarinic acetylcholine m1 receptor antagonistsPIPELINE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2356US2025171455A1Muscarinic acetylcholine m1 receptor antagonistsCONTINEUM THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2447US2018079745A1Pyrazolone compounds and uses thereofTEMPEST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2545US2021363152A1Aminoazine amidesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2640US9862708B2Pyrazolone compounds and uses thereofTEMPEST THERAPEUTICS INC·Filed 2015·Granted Jan 9, 2018·0 cites·19 claims
- 2734US2011257233A1Benzoisothiazolones as inhibitors of phosphomannose isomeraseSANFORD BURNHAM MED RES INST·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yalda Bravo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →